Bellecapital International Ltd. Decreases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bellecapital International Ltd. reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,220 shares of the biopharmaceutical company’s stock after selling 380 shares during the quarter. Regeneron Pharmaceuticals accounts for about 2.4% of Bellecapital International Ltd.’s investment portfolio, making the stock its 16th largest holding. Bellecapital International Ltd.’s holdings in Regeneron Pharmaceuticals were worth $12,190,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. Pamalican Asset Management Ltd bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth $4,915,000. Intact Investment Management Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $356,000. Rhenman & Partners Asset Management AB lifted its position in shares of Regeneron Pharmaceuticals by 11.4% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company’s stock worth $30,956,000 after buying an additional 4,457 shares during the last quarter. Fagan Associates Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 42.2% in the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock valued at $9,205,000 after buying an additional 3,832 shares during the period. Finally, GAMMA Investing LLC grew its position in shares of Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock valued at $517,291,000 after buying an additional 814,713 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of recent research reports. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $700.00 to $580.00 in a report on Friday, May 30th. Morgan Stanley cut their price target on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an “overweight” rating on the stock in a report on Monday, June 2nd. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 22nd. The Goldman Sachs Group dropped their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating on the stock in a research report on Wednesday, April 30th. Finally, Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $836.48.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $518.60 on Thursday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The company’s 50-day moving average price is $564.76 and its two-hundred day moving average price is $653.10. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20. The stock has a market cap of $55.99 billion, a PE ratio of 13.55, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter last year, the firm posted $9.55 EPS. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.68%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.